Merger takes Jacksonville immunotherapy company to Houston
TapImmune Inc. (Nasdaq: TPIV), the Jacksonville-based developer of cancer fighting immunotherapies, is merging with Marker Therapeutics Inc., a Minnesota-based developer of similar T-cell therapies. The newly formed company will be based in Houston, due to a strategic alliance with the Baylor College of Medicine.
TapImmune and Marker will each own half of the company, though the deal is still subject to the approval of TapImmune's stockholders. Marker is privately held. The combined company will…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Will Robinson Source Type: news
More News: Baylor College of Medicine | Biotechnology | Cancer | Cancer & Oncology | Health Management | Immunotherapy | Mergers and Aquisitions